- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
A case of severe cardiac adverse effects with IV Metoclopramide
Physicians are usually confronted with a question which antiemetic to use and whether Metoclopramide is a safe alternative to Domperidone. Peripheral antidopaminergic medication is frequently prescribed to treat nausea and vomiting. Metoclopramide has been suggested as a relatively safe alternative to domperidone which is ill-famed for its severe cardiac adverse effects.
According to history, an 83-year-old female came to the emergency room because of persistent nausea, vomiting and weight loss of 5 kg in 1 month. Her investigations to find out causative factor including abdominal ultrasound, thoracal and abdominal computed tomography (CT) scan and gastroscopy did not provide an explanation for her symptoms. She reported to have hypertension, osteoarthritis and depressive disorder, and her cardiac history consisted of supraventricular extrasystoles and mild hypertension.
Her investigations including kidney function and serum electrolytes turned out to be within normal range normal. She had been taking perindopril 2 mg once a day, mirtazapine 10 mg once a day, acetaminophen 500 mg three times a day and temazepam 10 mg once a day for her associated medical conditions. A routine electrocardiogram (ECG) showed normal sinus rhythm with a frequency of 72 beats per min (bpm) without conduction disorders. Because of severe nausea, she received 10 mg of metoclopramide intravenously. The rate of injection was not registered, but we assume a slow speed (over at least 3 min) in accordance with the hospital protocol.
Shortly afterward, she turned pale, started transpiring and became briefly unconscious. The heart monitor showed a bradycardia of 40 bpm and blood pressure of 69/44 mmHg. A second ECG was performed at that time, 15 min after the first ECG, and showed a nodal escape rhythm with retrograde atrial activation with normal QRS and QT duration. She was immediately given intravenous sodium chloride (0.9%) and her heart rate and blood pressure normalized within 20 min.
A rechallenge with metoclopramide was not performed. The severity of the adverse drug reaction was rated as severe (level 5) on the Modified Hartwig and Siegel Severity Assessment Scale. According to the preventability assessment using the Schumock scale, the adverse drug reaction was rated as unpreventable.
For more details click on the link:
https://doi.org/10.1007/s40800-018-0090-3
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd